It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Heterotrimeric G proteins are the main signalling effectors for G protein-coupled receptors. Understanding the distinct functions of different G proteins is key to understanding how their signalling modulates physiological responses. Pertussis toxin, a bacterial AB5 toxin, inhibits Gαi/o G proteins and has proven useful for interrogating inhibitory G protein signalling. Pertussis toxin, however, does not inhibit one member of the inhibitory G protein family, Gαz. The role of Gαz signalling has been neglected largely due to a lack of inhibitors. Recently, the identification of another Pertussis-like AB5 toxin was described. Here we show that this toxin, that we call OZITX, specifically inhibits Gαi/o and Gαz G proteins and that expression of the catalytic S1 subunit is sufficient for this inhibition. We identify mutations that render Gα subunits insensitive to the toxin that, in combination with the toxin, can be used to interrogate the signalling of each inhibitory Gα G protein.
A recently identified pertussis toxin-like AB5 toxin, OZITX, is found to inhibit Gαi/o and Gαz G proteins. In combination with directed mutations, it is a useful tool for interrogating Gαi/o/z G protein subunits individually.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, UK (GRID:grid.415598.4) (ISNI:0000 0004 0641 4263); Centre of Membrane Proteins and Receptors, University of Birmingham and University of Nottingham, Nottingham, UK (GRID:grid.4563.4) (ISNI:0000 0004 1936 8868)
2 Columbia University, Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112); NNF Center for Basic Metabolic Research, Section for Metabolic Receptology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
3 Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, UK (GRID:grid.415598.4) (ISNI:0000 0004 0641 4263); Centre of Membrane Proteins and Receptors, University of Birmingham and University of Nottingham, Nottingham, UK (GRID:grid.4563.4) (ISNI:0000 0004 1936 8868)
4 University of Melbourne, Department of Biochemistry and Molecular Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia (GRID:grid.418025.a) (ISNI:0000 0004 0606 5526)
5 Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
6 Plant and Soil Science and Centre for AgriBioscience, La Trobe University, Department of Animal, Bundoora, Australia (GRID:grid.1018.8) (ISNI:0000 0001 2342 0938)
7 Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
8 Computational Chemistry and Molecular Biophysics Section, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, USA (GRID:grid.420090.f) (ISNI:0000 0004 0533 7147)
9 Columbia University, Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112)